Full-Life Pharmaceuticals Completes Nearly RMB 250 Million Series A Financing to Advance Radiopharmaceutical Pipeline and Isotope Production Platform

Shanghai, China and Brussels, Belgium, May 26, 2022: Full-Life Technologies today announced the completion of its Series A financing round, raising nearly RMB 250 million. The proceeds from this round will be used to advance the development of its oncology radiopharmaceutical product pipeline and its production platform for medical radioisotopes. The round was led by Sequoia China, with participation from Yinglian Health Fund, Jiachen Capital, Chende Capital, and Kunlun Capital.

Mr. Sun Peiqi, Co-founder, Chairman, and Chief Operating Officer of Full-Life Technologies, stated, “Investment from world-class venture capital firms such as Sequoia China demonstrates strong confidence in our strategy, team, and the progress we have achieved to date. This round of financing will enable us to advance our drug candidates into clinical human studies next year and accelerate the development of our global radioisotope production and logistics capabilities.”

Dr. Cui Ping Gu, Managing Director at Sequoia China, stated, “Radiopharmaceuticals present a significant and highly promising opportunity for the development of precision oncology drugs. Full-Life Technologies is building a robust end-to-end solution to discover and develop innovative next-generation radiopharmaceuticals for cancer patients. The company has assembled an exceptional team to realize this vision and has rapidly established a rich and differentiated product pipeline.”

Full-Life Technologies’ drug discovery platform comprises single-domain antibodies, peptides, and radionuclide linkers. Furthermore, the company matches candidate compounds with therapeutic and diagnostic radionuclides, generating pharmacokinetic data that can effectively guide the selection of clinical trial participants.

Sequoia China is committed to helping entrepreneurs build enduring, great companies by providing its portfolio companies with abundant global resources and valuable historical expertise. As “entrepreneurs behind entrepreneurs,” Sequoia China focuses on investment opportunities in technology, consumer, and healthcare sectors. Over the past 17 years, Sequoia China has invested in more than 900 enterprises characterized by distinct technological advantages, innovative business models, high growth potential, and strong development prospects.

Full-Life Technologies Limited (“Full-Life Technologies”) is a comprehensive, international radiopharmaceutical therapy company headquartered in Shanghai, with business operations extending across Europe. We are dedicated to building an integrated industry chain encompassing the production, research, development, and commercialization of radioligands, striving to deliver greater clinical benefits to patients. Our core platform is designed to address key challenges in the current field of radiopharmaceuticals, establishing an innovative translational and biological research platform for future radiopharmaceutical therapies. The company boasts a team of seasoned entrepreneurs and scientists who excel not only in managing biopharmaceutical enterprises but also possess deep expertise in the research and clinical development of radioisotopes. Our philosophy is “Empowering New Life, Linking the Future.”